At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 98 enrolled
Drug / intervention
alefacept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating alefacept and Narrow Band UVB Phototherapy for Plaque Psoriasis. Completed, enrolled 98 participants across 12 sites.
Detailed Summary
Assess the efficacy and safety of alefacept with nbUVB compared to alefacept alone in chronic plaque psoriasis subjects. Combination therapy may improve the clinical response to psoriatic subjects as both modalities have an effect on T cells
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada
CollaboratorsAstellas Pharma Canada, Inc.
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedApr 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.2 years ago
Interventions
alefaceptdrug
IM
Narrow Band UVB Phototherapyprocedure
UVB Phototherapy